Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
MarketMinute.com Stock News
October 15, 2012 at 17:26 PM EDT
Standard Review For Delcath's Liver Treatment
The Food and Drug Administration accepted Delcath Systems Inc.'s (
) liver cancer treatment for standard review rather than priority review sending the stock price tumbling 39 cents to close at $1.70.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here